文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus.

作者信息

Alexander Tobias, Krönke Jan, Cheng Qingyu, Keller Ulrich, Krönke Gerhard

机构信息

Charité-Universitätsmedizin Berlin, Berlin, Germany.

出版信息

N Engl J Med. 2024 Sep 5;391(9):864-866. doi: 10.1056/NEJMc2407150.

DOI:10.1056/NEJMc2407150
PMID:39231352
Abstract
摘要

相似文献

[1]
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus.

N Engl J Med. 2024-9-5

[2]
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.

Lancet. 2021-8-21

[3]
Teclistamab in Relapsed or Refractory Multiple Myeloma.

N Engl J Med. 2022-8-11

[4]
Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis.

Mod Rheumatol. 2014-12-30

[5]
A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM.

Int J Hematol. 2025-2

[6]
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.

Ann Rheum Dis. 2024-10-21

[7]
Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.

Clin Pharmacokinet. 2018-6

[8]
Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.

Expert Rev Hematol. 2024-6

[9]
BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease.

N Engl J Med. 2024-9-5

[10]
Interstitial granulomatous dermatitis associated with lupus: A case report.

Reumatol Clin. 2017

引用本文的文献

[1]
Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases.

Nat Rev Rheumatol. 2025-9-1

[2]
[Evidence and updated guidelines of the European Society for Blood and Marrow Transplantation on autologous hematopoietic stem cell transplantation in inflammatory rheumatic diseases].

Z Rheumatol. 2025-8-21

[3]
Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.

Bone Marrow Transplant. 2025-8-20

[4]
Advances in the treatment of systemic lupus erythematosus.

Nat Rev Drug Discov. 2025-7-17

[5]
Immunotargets and Therapy for Systemic Lupus Erythematosus.

Immunotargets Ther. 2025-6-24

[6]
Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management.

Cell Mol Biol Lett. 2025-6-16

[7]
Teclistamab-Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma.

EJHaem. 2025-5-25

[8]
Insights from the 2024 pediatric rheumatology basic/translational years in review.

Pediatr Rheumatol Online J. 2025-5-23

[9]
Fibroblasts in immune responses, inflammatory diseases and therapeutic implications.

Nat Rev Rheumatol. 2025-5-14

[10]
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.

Nat Med. 2025-4-17

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索